Cue Biopharma, Inc. (CUE)

Market Cap	63.98M
Revenue (ttm)	9.53M
Net Income (ttm)	-44.61M
Shares Out	63.35M
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	596,097
Open	1.000
Previous Close	1.020
Day's Range	0.990 - 1.090
52-Week Range	0.450 - 3.200
Beta	1.63
Analysts	Strong Buy
Price Target	5.00 (+395.05%)
Earnings Date	Nov 14, 2024

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 2, 2018
• Employees: 53
• Stock Exchange: NASDAQ
• Ticker Symbol: CUE
• Website: https://www.cuebiopharma.com

Financial Performance

In 2023, Cue Biopharma's revenue was $5.49 million, an increase of 340.96% compared to the previous year's $1.25 million. Losses were -$50.73 million, -4.30% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for CUE stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 395.05% from the latest price.

Price Target

$5.0

(395.05% upside)

Analyst Consensus: Strong Buy